Calliditas Therapeutics announces that its partner Viatris Pharmaceutical Japan has initiated a Phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese patients with IgA nephropathy. The clinical trial is a bridging study requiring a limited number of Japanese patients to participate in a study similar in design to that of the global NefIgArd trial.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CALT:
- Calliditas Therapeutics announces USPTO issues patent for setanaxib
- Calliditas Therapeutics’ Annual Meeting Highlights
- Calliditas Therapeutics downgraded to Hold from Buy at Pareto
- Calliditas Therapeutics downgraded to Hold from Buy at SEB Equities
- Wynn Resorts upgraded, PayPal initiated: Wall Street’s top analyst calls